Renalase, Catecholamine and Nitric Oxide Changes Before and After Sodium Nitroprusside Administration to Patients who Develop Post-Coronary Artery By-Pass (CABG) Hypertension
Keywords:Renalase, Catecholamines, Nitric Oxide, Sodium Nitroprusside, Coronary Artery Bypass, Hypertension
Background: Hypertension develops at a rate of 33 to 70% after Coronary artery bypass grafting (CABG) operations. One of the most commonly used drugs to control hypertension is sodium nitroprusside (SNP). Additionally, renalase enzyme destroys catecholamines and mediates the regulation (reduction) of blood pressure. Thus, this clinical study aims to reveal how renalase, catecholamines and nitric oxide (NO) change and how certain hemodynamic parameters are affected in randomly and prospectively selected cases who are administered SNP for the treatment of blood pressure elevation within 6 to 8 hours after CABG surgery.
Methods: The study included 26 patients who developed hypertension after CABG, 12 patients who had normal blood pressure after CABG, and 22 healthy individuals. Renalase and catecholamine levels of the patients were measured using ELISA method and NO levels were determined by spectrophotometry.
Results: Renalase and NO levels of the patients who developed hypertension after CABG were found statistically significantly lower than those of healthy controls and patients who did not develop hypertension after CABG, while catecholamine levels were significantly higher in the former. After SNP was started, renalase and NO levels increased, and a significant decrease was observed in the catecholamine levels. Additionally, administration of SNP produced a slight increase in the heart rate and a decrease in systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and means arterial pressure (MAP).
Conclusion: SNP elevates NO and renalase levels; thus, administration of renalase preparations, which act in the destruction of catecholamines to contain persistent hypertension that develops in association with catecholamine elevation after CABG surgery, along with SNP and other medications used to lower blood pressure can be an effective therapeutic method to control hypertension.
Aydin S, Aydin S, Nesimi Eren M, et al. 2013. The cardiovascular system and the biochemistry of grafts used in heart surgery. Springerplus 2:612.
Aydin S, Eren MN, Kalayci M, Yilmaz M, Aydin S. 2014. Analysis of hemodynamics and biochemical profile during coronary artery bypass surgery using cardiopulmonary bypass. Heart Health Open Access 1:1.
Burns N, Brett L, Olverman HJ, Nagatsu T, Lee MR, Williams BC. 1996. The role of L-aromatic amino acid decarboxylase in serotonin-stimulated aldosterone secretion in response to salt intake. Endocr Res 22:577-8.
Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 42:1206-52.
de Champlain J. 1990. Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertens Suppl 8:S77-85.
Desir GV, Peixoto AJ. 2014. Renalase in hypertension and kidney disease. Nephrol Dial Transplant 29:22-8.
Dufour S, Lebon V, Shulman GI, Petersen KF. 2009. Regulation of net hepatic glycogenolysis and gluconeogenesis by epinephrine in humans. Am J Physiol Endocrinol Metab 297:E231-5.
Erturk M, Acikel U, Silistreli E, Hazan E, Oto O. 1998. The Comparison of the Efficacies of Isradipine and Sodium Nitroprusside on the Hypertension After Coronary Bypass Operations. GKDC Dergisi 6:190-7.
Estafanous FG, Tarazi RC, Viljoen JF, el-Tawil MY. 1973. Systemic hypertension following myocardial revascularization. Am Heart J 85:732-8.
Friederich JA, Butterworth JF. 1995. Sodium nitroprusside: twenty years and counting. Anesth Analg 81:152-62.
Gayathri N, Balasubramanian N. 1999. Spectrophotometric determination of nitrogen dioxide, nitrite and nitrate with Neutral Red. Analusis 27:174.
Gibson CM, Davis S, Bradford D. 2017. Examining the Use of Sodium Nitroprusside in Coronary Artery Bypass Grafting: Is the Benefit Worth the Cost? Hosp Pharm 52:502-7.
Grossi L, D'Angelo S. 2005. Sodium nitroprusside: mechanism of NO release mediated by sulfhydryl-containing molecules. J Med Chem 48:2622-6.
Hennebry SC, Eikelis N, Socratous F, Desir G, Lambert G, Schlaich M. 2010. Renalase, a novel soluble FAD-dependent protein, is synthesized in the brain and peripheral nerves. Mol Psychiatry 15:234-6.
Hottinger DG, Beebe DS, Kozhimannil T, Prielipp RC, Belani KG. 2014. Sodium nitroprusside in 2014: A clinical concepts review. J Anaesthesiol Clin Pharmacol 30:462-71.
Kobori H, Nangaku M, Navar LG, Nishiyama A. 2007. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59:251-87.
Lavvrence CJ, Lestrade A, Chan E, Du Lange S. 1993. Comparative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery. Acta Anaesthesiol Scand 99:48-52.
Lee HT, Kim JY, Kim M, et al. 2013. Renalase protects against ischemic AKI. J Am Soc Nephrol 24:445-55.
Lema G, Urzua J, Jalil R, et al. 2009. Decreased nitric oxide products in the urine of patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 23:188-94.
Leslie J, Brister N, Levy JH, et al. 1994. Treatment of postoperative hypertension after coronary artery bypass surgery. Double-blind comparison of intravenous isradipine and sodium nitroprusside. Circulation 90:II256-61.
Lomivorotov VV, Efremov SM, Kirov MY, Fominskiy EV, Karaskov AM. 2017. Low-Cardiac-Output Syndrome After Cardiac Surgery. J Cardiothorac Vasc Anesth 31:291-308.
Mannelli M, Pupilli C, Lanzillotti R, Ianni L, Serio M. 1990. Catecholamines and blood pressure regulation. Horm Res 34:156-60.
Messan F, Tito A, Gouthon P, et al. 2017. Comparison of Catecholamine Values Before and After Exercise-Induced Bronchospasm in Professional Cyclists. Tanaffos 16:136-43.
Momota Y, Kaneda K, Arishiro K, Kishimoto N, Kanou S, Kotani J. 2010. Changes in blood pressure during induction of anesthesia and oral and maxillofacial surgery by type and timing of discontinuation of antihypertensive drugs. Anesth Prog Spring 57:13-7.
Muralidhar K. 2002. Central venous pressure and pulmonary capillary wedge pressure monitoring. Indian J Anaesth 46:298-303.
Musizza B, Ribaric S. 2010. Monitoring the depth of anaesthesia. Sensors (Basel) 10:10896-935.
Najmaii S, Redford D, Larson DF. 2006. Hyperglycemia as an effect of cardiopulmonary bypass: intra-operative glucose management. J Extra Corpor Technol 38:168-73.
Narayanai B, Sunil K. 2009. A Spectrophotometric Method for the Determination of Nitrite and Nitrate. Eurasian J Anal Chem 4:204-14.
Quelhas-Santos J, Sampaio-Maia B, Simões-Silva L, et al. 2013. Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidney. J Hypertens 31:543-52.
Ranabir S, Reetu K. 2011. Stress and hormones. Indian J Endocrinol 15:18-22.
Sealy WC. 1967. Coarctation of the aorta and hypertension. Ann Thorac Surg 3:15-28.
Sizova D, Velazquez H, Sampaio-Maia B, Quelhas-Santos J, Pestana M, Desir GV. 2013. Renalase regulates renal dopamine and phosphate metabolism. Am J Physiol Renal Physiol 305:F839-44.
Susan M. Undenvood, Robert O. Feneck, Simon W. Davies, Robin K. Walesby, Martin W. Lunnon. 1989. Use of isradipine in hypertension following coronary artery bypass surgery. Amer J Med 86:81-7.
Takemoto F, Cohen HT, Satoh T, Katz AI. 1992. Dopamine inhibits Na/K-ATPase in single tubules and cultured cells from distal nephron. Pflugers Arch 421:302-6.
Telenius-Berg M, Adolfsson L, Berg B, et al. 1987. Catecholamine release after physical exercise. A new provocative test for early diagnosis of pheochromocytoma in multiple endocrine neoplasia type 2. Acta Med Scand 222:351-9.
Tilders FJ, Berkenbosch F, Vermes I, Linton EA, Smelik PG. 1985. Role of epinephrine and vasopressin in the control of the pituitary-adrenal response to stress. Fed Proc 44:155-60.
Varon J, Marik PE. 2008. Perioperative hypertension management. Vasc Health Risk Manag 4:615-27.
Wang L, Velazquez H, Moeckel G, et al. 2014. Renalase prevents AKI independent of amine oxidase activity. J Am Soc Nephrol 25:1226-35.
Wang X, Armando I, Upadhyay K, Pascua A, Jose PA. 2009. The regulation of proximal tubular salt transport in hypertension: an update. Curr Opin Nephrol Hypertens 18:412-20.
Whelton PK, Flaherty JT, MacAllister NP, et al. 1980. Hypertension following coronary artery bypass surgery. Role of preoperative propranolol therapy. Hypertension 2:291-8.
Xu J, Li G, Wang P, et al. 2005. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 115:1275-80.
Zhao B, Zhao Q, Li J, Xing T, Wang F, Wang N. 2015. Renalase protects against contrast-induced nephropathy in Sprague-Dawley rats. PLoS One 10:e0116583.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).